Personalis (NASDAQ:PSNL – Get Free Report) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it contrast to its peers? We will compare Personalis to related businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.
Valuation and Earnings
This table compares Personalis and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Personalis | $69.65 million | -$81.27 million | -14.46 |
| Personalis Competitors | $2.28 billion | $55.11 billion | -13.40 |
Personalis’ peers have higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Personalis has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Personalis’ peers have a beta of 1.14, meaning that their average share price is 14% more volatile than the S&P 500.
Insider and Institutional Ownership
61.9% of Personalis shares are held by institutional investors. Comparatively, 54.9% of shares of all “Life Sciences Tools & Services” companies are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Personalis and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Personalis | 1 | 7 | 3 | 0 | 2.18 |
| Personalis Competitors | 947 | 3159 | 5473 | 177 | 2.50 |
Personalis presently has a consensus price target of $14.54, suggesting a potential downside of 7.77%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.79%. Given Personalis’ peers stronger consensus rating and higher possible upside, analysts clearly believe Personalis has less favorable growth aspects than its peers.
Profitability
This table compares Personalis and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Personalis | -153.84% | -46.47% | -35.30% |
| Personalis Competitors | -540.73% | -166.48% | -13.59% |
Summary
Personalis peers beat Personalis on 9 of the 13 factors compared.
About Personalis
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
